The effect of ginger-quince compound on nausea and vomiting induced by chemotherapy and radiotherapy

Evaluating the effect of combined ginger and quince on nausea and vomiting in cancer patients undergoing concurrent chemotherapy and radiotherapy

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2012113011615N1

Enrollment

240

Registered

2013-09-11

Start date

2013-03-15

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nausea and vomiting. Nausea and vomiting

Interventions

Intervention 1: Cases is prescribed standardized ginger and quince capsules three times a day, within 15 minutes of each meal, starting from 3 days before chemotherapy until completion of radiothera

Treatment - Drugs

Cases is prescribed standardized ginger and quince capsules three times a day, within 15 minutes of each meal, starting from 3 days before chemotherapy until completion of radiotherapy period ( six

Control group is prescribed placebo three times a day, within 15 minutes of each meal, starting from 3 days before chemotherapy until completion of radiotherapy period ( six weeks)

Eligibility

Sex/Gender

All

Age

18 Years to 149 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria:Suffering from cancer; definitely diagnosed by a pathologist; 18?? year-old or more; under chemotherapy treatments; simultaneous radiotherapy treatments inducing ?nausea and vomiting such as whole body or upper abdomen RT. Exclusion criteria: Warfarin and Heparin ?treatment; ASA consuming more than 80 mg; history of? blood disorders; history of severe thrombocytopenia; allergy to ginger or consuming it during the ?past week; gastro-intestinal cancers; having nausea and vomiting induced by factors except ?chemotherapy or radiotherapy such as CNS tumors, HTN, renal failure or hepatic disorders; gastrointestinal ?problems like gastric or peptic ulcers; forgetting the use of capsules three consecutive times or more.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Nausea severity. Timepoint: During the intervention, weekly. Method of measurement: Visual analogue scale.;Number of vomiting. Timepoint: During the intervention, weekly. Method of measurement: Data registration form.;Duration of vomiting. Timepoint: During the intervention, weekly. Method of measurement: Data registration form.;Duratin of nausea. Timepoint: During the intervention, weekly. Method of measurement: Data registration form.	—

Measure

Time frame

Nausea severity. Timepoint: During the intervention, weekly. Method of measurement: Visual analogue scale.;Number of vomiting. Timepoint: During the intervention, weekly. Method of measurement: Data registration form.;Duration of vomiting. Timepoint: During the intervention, weekly. Method of measurement: Data registration form.;Duratin of nausea. Timepoint: During the intervention, weekly. Method of measurement: Data registration form.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMotahare ??Sadat Mousavian

Medicin college, Tehran university of medical sciences and health services

m.mousavian145@yahoo.com+98 21 81631

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026